{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T02:17:45Z","timestamp":1773281865869,"version":"3.50.1"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,7,24]],"date-time":"2018-07-24T00:00:00Z","timestamp":1532390400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002066","name":"GSK","doi-asserted-by":"publisher","award":["HO-16-16350"],"award-info":[{"award-number":["HO-16-16350"]}],"id":[{"id":"10.13039\/501100002066","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.rmed.2018.07.009","type":"journal-article","created":{"date-parts":[[2018,7,18]],"date-time":"2018-07-18T09:10:34Z","timestamp":1531905034000},"page":"73-80","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Clinical characteristics and medication patterns in patients with COPD prior to initiation of triple therapy with ICS\/LAMA\/LABA: A retrospective study"],"prefix":"10.1016","volume":"142","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1681-9710","authenticated-orcid":false,"given":"Michael","family":"Bogart","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard H.","family":"Stanford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tyler","family":"Reinsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Hull","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ami","family":"Buikema","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin","family":"Hulbert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmed.2018.07.009_bib1","author":"Global Initiative for Chronic Obstructive Lung Disease"},{"key":"10.1016\/j.rmed.2018.07.009_bib2","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.2147\/COPD.S122282","article-title":"Major air pollutants and risk of COPD exacerbations: a systematic review and meta-analysis","volume":"11","author":"Li","year":"2016","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"issue":"12","key":"10.1016\/j.rmed.2018.07.009_bib3","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1136\/thx.51.12.1216","article-title":"Free radical activity and pro-inflammatory effects of particulate air pollution (PM10) in vivo and in vitro","volume":"51","author":"Li","year":"1996","journal-title":"Thorax"},{"issue":"11","key":"10.1016\/j.rmed.2018.07.009_bib4","first-page":"289","article-title":"Employment and activity limitations among adults with chronic obstructive pulmonary disease\u2013United States, 2013","volume":"64","author":"Wheaton","year":"2015","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"10.1016\/j.rmed.2018.07.009_bib5","author":"National Center for Health Statistics"},{"key":"10.1016\/j.rmed.2018.07.009_bib6","first-page":"235","article-title":"The clinical and economic burden of chronic obstructive pulmonary disease in the USA","volume":"5","author":"Guarascio","year":"2013","journal-title":"Clinicoecon. Outcomes Res."},{"issue":"1","key":"10.1016\/j.rmed.2018.07.009_bib7","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/resp.12660","article-title":"Global burden of COPD","volume":"21","author":"L\u00f3pez-Campos","year":"2016","journal-title":"Respirology"},{"key":"10.1016\/j.rmed.2018.07.009_bib8","series-title":"COPD Foundation's Pocket Consultant Guide","author":"COPD Foundation","year":"2017"},{"issue":"3","key":"10.1016\/j.rmed.2018.07.009_bib9","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1124\/pr.111.004580","article-title":"Pharmacology and therapeutics of bronchodilators","volume":"64","author":"Cazzola","year":"2012","journal-title":"Pharmacol. Rev."},{"issue":"1","key":"10.1016\/j.rmed.2018.07.009_bib10","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1378\/chest.125.1.249","article-title":"The role of long-acting bronchodilators in the management of stable COPD","volume":"125","author":"Tashkin","year":"2004","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.rmed.2018.07.009_bib11","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/1465-9921-14-49","article-title":"Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease","volume":"14","author":"Tashkin","year":"2013","journal-title":"Respir. Res."},{"issue":"1","key":"10.1016\/j.rmed.2018.07.009_bib12","article-title":"Disease severity and symptoms among patients receiving monotherapy for COPD","volume":"20","author":"Dransfield","year":"2010","journal-title":"Prim Care Respir Med"},{"issue":"12","key":"10.1016\/j.rmed.2018.07.009_bib13","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1056\/NEJMoa0909883","article-title":"Susceptibility to exacerbation in chronic obstructive pulmonary disease","volume":"363","author":"Hurst","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.rmed.2018.07.009_bib14","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1164\/rccm.201108-1553OC","article-title":"Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial","volume":"186","author":"Bafadhel","year":"2012","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"5","key":"10.1016\/j.rmed.2018.07.009_bib15","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1183\/09031936.00146306","article-title":"Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial","volume":"29","author":"Siva","year":"2007","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2018.07.009_bib16","author":"Agency for Healthcare Research and Quality (AHRQ)"},{"issue":"6","key":"10.1016\/j.rmed.2018.07.009_bib17","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/aje\/kwq433","article-title":"Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries","volume":"173","author":"Quan","year":"2011","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.rmed.2018.07.009_bib18","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2147\/COPD.S122013","article-title":"Initiation of triple therapy maintenance treatment among patients with COPD in the US","volume":"12","author":"Simeone","year":"2017","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"issue":"11","key":"10.1016\/j.rmed.2018.07.009_bib19","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1136\/thx.2009.113662","article-title":"Adherence to inhaled therapy, mortality and hospital admission in COPD","volume":"64","author":"Vestbo","year":"2009","journal-title":"Thorax"},{"issue":"2","key":"10.1016\/j.rmed.2018.07.009_bib20","first-page":"92","article-title":"Impact of nonadherence to inhaled corticosteroid\/LABA therapy on COPD exacerbation rates and healthcare costs in a commercially insured US population","volume":"10","author":"Davis","year":"2017","journal-title":"American health & drug benefits"},{"key":"10.1016\/j.rmed.2018.07.009_bib21","first-page":"2207","article-title":"The inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UK","volume":"10","author":"Brusselle","year":"2015","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"issue":"4","key":"10.1016\/j.rmed.2018.07.009_bib22","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1164\/rccm.201502-0235LE","article-title":"Blood eosinophils: a biomarker of response to extrafine beclomethasone\/formoterol in chronic obstructive pulmonary disease","volume":"192","author":"Siddiqui","year":"2015","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"5","key":"10.1016\/j.rmed.2018.07.009_bib23","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S2213-2600(16)00100-4","article-title":"Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial","volume":"4","author":"Watz","year":"2016","journal-title":"Lancet Respir Med"},{"issue":"6","key":"10.1016\/j.rmed.2018.07.009_bib24","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S2213-2600(15)00106-X","article-title":"Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials","volume":"3","author":"Pascoe","year":"2015","journal-title":"Lancet Respir Med"},{"issue":"2","key":"10.1016\/j.rmed.2018.07.009_bib25","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.chest.2016.10.003","article-title":"Eosinophils in COPD exacerbations are associated with increased readmissions","volume":"151","author":"Couillard","year":"2017","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.rmed.2018.07.009_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/15412555.2015.1034256","article-title":"Efficacy and safety of umeclidinium added to fluticasone propionate\/salmeterol in patients with COPD: results of two randomized, double-blind studies","volume":"13","author":"Siler","year":"2016","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"issue":"6","key":"10.1016\/j.rmed.2018.07.009_bib27","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1136\/thoraxjnl-2014-206670","article-title":"Glycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol\/fluticasone in patients with COPD: the GLISTEN study\u2014a randomised controlled trial","volume":"70","author":"Frith","year":"2015","journal-title":"Thorax"},{"issue":"7","key":"10.1016\/j.rmed.2018.07.009_bib28","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1136\/thx.2007.087213","article-title":"Superiority of \u201ctriple\u201d therapy with salmeterol\/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD","volume":"63","author":"Singh","year":"2008","journal-title":"Thorax"},{"issue":"8","key":"10.1016\/j.rmed.2018.07.009_bib29","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1164\/rccm.200904-0492OC","article-title":"Efficacy and tolerability of budesonide\/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease","volume":"180","author":"Welte","year":"2009","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"10082","key":"10.1016\/j.rmed.2018.07.009_bib30","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/S0140-6736(17)30188-5","article-title":"Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial","volume":"389","author":"Vestbo","year":"2017","journal-title":"Lancet"},{"issue":"10048","key":"10.1016\/j.rmed.2018.07.009_bib31","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S0140-6736(16)31354-X","article-title":"Single inhaler triple therapy versus inhaled corticosteroid plus long-acting \u03b2 2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial","volume":"388","author":"Singh","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.rmed.2018.07.009_bib32","first-page":"1","article-title":"Once-daily triple therapy in patients with COPD: patient-reported symptoms and quality of life","author":"Tabberer","year":"2018","journal-title":"Adv. Ther."},{"issue":"4","key":"10.1016\/j.rmed.2018.07.009_bib33","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1164\/rccm.201703-0449OC","article-title":"FULFIL trial: once-daily triple therapy for patients with chronic obstructive pulmonary disease","volume":"196","author":"Lipson","year":"2017","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"18","key":"10.1016\/j.rmed.2018.07.009_bib34","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1056\/NEJMoa1713901","article-title":"Once-Daily single-inhaler triple versus dual therapy in patients with COPD","volume":"378","author":"Lipson","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.rmed.2018.07.009_bib35","series-title":"Trelegy: European SmPC and Patient Information","author":"GSK","year":"2018"},{"key":"10.1016\/j.rmed.2018.07.009_bib36","author":"GSK"}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611118302397?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611118302397?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T11:42:15Z","timestamp":1760614935000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611118302397"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":36,"alternative-id":["S0954611118302397"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2018.07.009","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical characteristics and medication patterns in patients with COPD prior to initiation of triple therapy with ICS\/LAMA\/LABA: A retrospective study","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2018.07.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}